JPM26: AstraZeneca bids to accelerate oncology R&D with Modella AI acquisition
The company is embracing AI integration throughout drug development, aiming to improve efficiency and drive portfolio expansion.
Therapy Area
Drugmakers welcome FDA’s GLP-1RA suicide warning removal request
JPM26: Madrigal seeks early dominance in MASH through strategic acquisitions
JPM26: Pfizer’s Metsera deal supercharges its obesity strategy
JPM26: J&J leans on immunology launches to fuel annual growth
JPM26: HIV pipeline dosing optionality gives Gilead advantage
JPM26: Revolution Medicines in spotlight as industry gears up for dealmaking spree
Eli Lilly acquires inflammatory specialist Ventyx for $1.2bn
